An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
Get Alerts DYAI Hot Sheet
Join SI Premium – FREE
SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision
New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) ("Dyadic" or the "Company") is entering the next phase of its growth strategy as it expands commercialization efforts across Life Sciences, Food & Nutrition, and Bio-industrial markets. SmallCaps Daily sat down with President and Chief Operating Officer Joe Hazelton to discuss the Company's product portfolio, strategic partnerships, and growing opportunities in non-animal proteins.
With commercial products now launched through partners, including ProLiant Health and Biologics, and additional products entering the market through direct sales and distribution agreements, Dyadic is focused on building recurring revenue streams while addressing the increasing demand for scalable, high-quality protein production.
To read the full article, visit:
https://smallcapsdaily.com/building-the-infrastructure-for-the-protein-economy
About Dyadic Applied BioSolutions, Inc.
Dyadic Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's proprietary Dapibus" and C1 expression systems support rapid, cost-effective, and flexible manufacturing.
For more information, please visit http://www.dyadic.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302301
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
- AAON rebrands its enterprise identity as The Aaon Group
- Leeward Capital Corp. Announces Appointments of Directors
Create E-mail Alert Related Categories
Newsfile, Press ReleasesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share